New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

Data ReadoutpositiveTissueCypher® Barrett's Esophagus TestPositive

AI Analysis

Summary

Castle Biosciences announced publication of a study demonstrating that its TissueCypher® Barrett's Esophagus Test changed clinical management in 90% of patients with non-dysplastic Barrett's Esophagus at an expert surgery center.

Outcome Details

Study showed TissueCypher® changed management in 90% of patients with non-dysplastic Barrett's Esophagus

Importance:5/10

Sentiment:

0.70

diagnostic testBarrett's Esophagusclinical studypublicationpatient management

Related Companies

$CSTL

Read the original article

Published by PR Newswire Biotech on September 28, 2026 11:00 AM

Read Original